About Novartis (NYSE:NVS)
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
Industry, Sector and Symbol
Trailing P/E Ratio24.1723076923077
Forward P/E Ratio14.74
Sales & Book Value
Annual Sales$49.11 billion
Price / Sales3.71
Cash Flow$7.52 per share
Price / Cash10.44
Book Value$32.03 per share
Price / Book2.45
Net Income$7.70 billion
Return on Equity16.03%
Return on Assets8.53%
Novartis (NYSE:NVS) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
How will Novartis' stock buyback program work?
Novartis announced that its Board of Directors has authorized a stock repurchase plan on Saturday, April 8th 2017, which authorizes the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 2.9% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its stock is undervalued.
How were Novartis' earnings last quarter?
Novartis AG (NYSE:NVS) issued its earnings results on Wednesday, January, 24th. The company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.04. The business earned $12.92 billion during the quarter, compared to the consensus estimate of $12.65 billion. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The business's revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.14 EPS. View Novartis' Earnings History.
When will Novartis make its next earnings announcement?
Where is Novartis' stock going? Where will Novartis' stock price be in 2018?
8 analysts have issued 12 month price targets for Novartis' stock. Their predictions range from $82.25 to $91.00. On average, they anticipate Novartis' share price to reach $87.75 in the next year. View Analyst Ratings for Novartis.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Roche (RHHBY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Sanofi (SNY), Bayer (BAYRY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Celgene (CELG), Biogen (BIIB), Allergan (AGN) and Vertex Pharmaceuticals (VRTX).
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Vasant Narasimhan M.D., Chief Executive Officer, Member of the Executive Committee
- Harry Kirsch, Chief Financial Officer, Member of the Executive Committee (Age 53)
- Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee (Age 61)
- Steven Baert, Head of Human Resources, Member of the Executive Committee (Age 44)
- F. Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee (Age 63)
- James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee (Age 46)
- Richard D. Francis, Chief Executive Officer of Sandoz, Member of the Executive Committee (Age 50)
- Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee (Age 51)
- Andre Wyss, President of Novartis Operations, Country President for Switzerland, Member of the Executive Committee (Age 51)
- Charlotte Pamer-Wieser Ph.D., Corporate Secretary
Has Novartis been receiving favorable news coverage?
News articles about NVS stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novartis earned a coverage optimism score of 0.21 on Accern's scale. They also gave news headlines about the company an impact score of 46.04 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Novartis' major shareholders?
Novartis' stock is owned by a number of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (0.64%), Parnassus Investments CA (0.41%), Fisher Asset Management LLC (0.29%), BlackRock Inc. (0.17%), Aristotle Capital Management LLC (0.14%) and Mawer Investment Management Ltd. (0.12%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.
Which institutional investors are selling Novartis stock?
NVS stock was sold by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , Sterling Capital Management LLC, Franklin Resources Inc., Millennium Management LLC, BB&T Securities LLC, OLD Mission Capital LLC, D.A. Davidson & CO. and BB&T Corp. View Insider Buying and Selling for Novartis.
Which institutional investors are buying Novartis stock?
NVS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Aristotle Capital Management LLC, Senzar Asset Management LLC, Fisher Asset Management LLC, FNY Partners Fund LP, Arrowstreet Capital Limited Partnership and Madison Investment Holdings Inc.. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.
How do I buy shares of Novartis?
Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novartis' stock price today?
One share of NVS stock can currently be purchased for approximately $78.56.
How big of a company is Novartis?
Novartis has a market capitalization of $185.12 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $3.25 on an earnings per share basis. Novartis employs 121,597 workers across the globe.
How can I contact Novartis?
Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]
MarketBeat Community Rating for Novartis (NVS)MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Novartis (NYSE:NVS) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||1.75||1.92||2.00||2.27|
|Ratings Breakdown: ||3 Sell Rating(s)|
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|4 Sell Rating(s)|
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|4 Sell Rating(s)|
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|2 Sell Rating(s)|
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$87.75||$84.41||$84.41||$84.44|
|Price Target Upside: ||11.70% upside||2.85% downside||0.67% upside||0.75% upside|
Novartis (NYSE:NVS) Consensus Price Target History
Novartis (NYSE:NVS) Analyst Ratings History
(Data available from 3/24/2016 forward)
Novartis (NYSE:NVS) Earnings History and Estimates Chart
Novartis (NYSE NVS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/24/2018||n/a||$1.16||$1.20||$12.65 billion||$12.92 billion||View||Listen|
|10/24/2017||9/30/2017||$1.25||$1.29||$12.21 billion||$12.41 billion||View||N/A|
|7/18/2017||Q2 17||$1.16||$1.22||$12.20 billion||$12.24 billion||View||N/A|
|4/25/2017||3/31/2017||$1.10||$1.13||$11.59 billion||$11.54 billion||View||N/A|
|1/25/2017||Q416||$1.12||$1.12||$12.44 billion||$12.32 billion||View||N/A|
|10/25/2016||Q316||$1.19||$1.23||$12.24 billion||$12.13 billion||View||Listen|
|7/19/2016||Q216||$1.18||$1.23||$12.33 billion||$12.47 billion||View||Listen|
|4/21/2016||Q116||$1.18||$1.17||$11.90 billion||$11.60 billion||View||Listen|
|1/27/2016||Q415||$1.18||$1.14||$12.64 billion||$12.52 billion||View||Listen|
|10/27/2015||Q315||$1.31||$1.27||$12.66 billion||$12.30 billion||View||Listen|
|7/21/2015||Q215||$1.20||$1.27||$12.45 billion||$12.70 billion||View||Listen|
|4/23/2015||Q115||$1.12||$1.33||$12.90 million||$11.94 billion||View||N/A|
|1/27/2015||Q314||$1.13||$1.21||$14.68 billion||$14.63 billion||View||N/A|
|10/28/2014||Q3 2014||$1.29||$1.28||$14.14 billion||$14.70 billion||View||N/A|
|7/17/2014||Q214||$1.36||$1.36||$14.83 billion||$14.64 billion||View||N/A|
|4/24/2014||Q1 2014||$1.33||$1.31||$14.25 billion||$14.02 billion||View||N/A|
|1/29/2014||Q413||$1.27||$1.20||$15.16 billion||$15.08 billion||View||N/A|
|10/22/2013||Q313||$1.31||$1.26||$14.28 billion||$14.34 billion||View||N/A|
|7/17/2013||Q213||$1.29||$1.30||$14.39 billion||$14.50 billion||View||N/A|
|4/24/2013||Q113||$1.28||$1.32||$14.02 million||$14.02 billion||View||N/A|
|1/23/2013||Q412||$1.19||$1.27||$14.42 billion||$14.80 billion||View||N/A|
Novartis (NYSE:NVS) Earnings Estimates
2018 EPS Consensus Estimate: $5.50
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Novartis (NYSE:NVS) Dividend Information
|Most Recent Dividend:||3/3/2017|
|Dividend Growth:||-0.50% (3 Year Average)|
|Payout Ratio:||91.69% (Trailing 12 Months of Earnings) |
55.91% (Based on This Year's Estimates)
51.83% (Based on Next Year's Estimates)
Novartis (NYSE:NVS) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Novartis (NYSE NVS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.76%
Novartis (NYSE NVS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/5/2017||Bioventures Ltd Novartis||Major Shareholder||Buy||266,667||$15.00||$4,000,005.00|| |
|5/11/2016||Institutes For Biomed Novartis||Major Shareholder||Buy||277,777||$18.00||$4,999,986.00|| |
|2/17/2016||Bioventures Ltd Novartis||Major Shareholder||Buy||375,000||$8.00||$3,000,000.00|| |
|9/22/2014||Bioventures Ltd Novartis||Major Shareholder||Buy||325,000||$15.00||$4,875,000.00|| |
Novartis (NYSE NVS) News Headlines
Novartis (NYSE:NVS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Novartis (NYSE:NVS) Income Statement, Balance Sheet and Cash Flow Statement
Novartis (NYSE NVS) Stock Chart for Saturday, March, 24, 2018